- Home
- ACNB vs VERV Comparison
ACNB vs VERV Comparison
Compare ACNB & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNB
- VERV
- Stock Information
- Founded
- ACNB 1857
- VERV 2018
- Country
- ACNB United States
- VERV United States
- Employees
- ACNB N/A
- VERV N/A
- Industry
- ACNB Major Banks
- VERV Medicinal Chemicals and Botanical Products
- Sector
- ACNB Finance
- VERV Health Care
- Exchange
- ACNB Nasdaq
- VERV Nasdaq
- Market Cap
- ACNB 430.6M
- VERV 384.2M
- IPO Year
- ACNB N/A
- VERV 2021
- Fundamental
- Price
- ACNB $41.29
- VERV $11.06
- Analyst Decision
- ACNB Strong Buy
- VERV Buy
- Analyst Count
- ACNB 4
- VERV 9
- Target Price
- ACNB $50.00
- VERV $14.75
- AVG Volume (30 Days)
- ACNB 23.9K
- VERV 7.8M
- Earning Date
- ACNB 07-23-2025
- VERV 08-07-2025
- Dividend Yield
- ACNB 3.29%
- VERV N/A
- EPS Growth
- ACNB N/A
- VERV N/A
- EPS
- ACNB 2.79
- VERV N/A
- Revenue
- ACNB $113,448,000.00
- VERV $59,613,000.00
- Revenue This Year
- ACNB $38.67
- VERV $27.75
- Revenue Next Year
- ACNB $5.26
- VERV N/A
- P/E Ratio
- ACNB $14.80
- VERV N/A
- Revenue Growth
- ACNB 8.66
- VERV 271.44
- 52 Week Low
- ACNB $31.16
- VERV $2.87
- 52 Week High
- ACNB $50.72
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- ACNB 47.07
- VERV 84.74
- Support Level
- ACNB $40.15
- VERV $5.88
- Resistance Level
- ACNB $43.00
- VERV $11.41
- Average True Range (ATR)
- ACNB 0.92
- VERV 0.49
- MACD
- ACNB -0.10
- VERV 0.64
- Stochastic Oscillator
- ACNB 40.00
- VERV 95.00
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.